Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 9.9%

Posted by on Jun 17th, 2022

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating)’s stock price rose 9.9% on Friday . The stock traded as high as $11.89 and last traded at $11.87. Approximately 10,165 shares traded hands during trading, a decline of 97% from the average daily volume of 351,168 shares. The stock had previously closed at $10.80.

YMAB has been the subject of several recent research reports. Wedbush dropped their target price on shares of Y-mAbs Therapeutics from $28.00 to $21.00 and set an “outperform” rating for the company in a report on Tuesday, May 10th. HC Wainwright restated a “buy” rating and set a $63.00 target price on shares of Y-mAbs Therapeutics in a report on Friday, April 29th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, Y-mAbs Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $31.60.

The firm has a market capitalization of $524.08 million, a PE ratio of -4.40 and a beta of 1.44. The business’s fifty day moving average price is $11.06 and its 200 day moving average price is $11.74.

Y-mAbs Therapeutics (NASDAQ:YMAB – Get Rating) last issued its quarterly earnings results on Monday, May 9th. The company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.10. The business had revenue of $10.49 million during the quarter, compared to the consensus estimate of $11.10 million. Y-mAbs Therapeutics had a negative net margin of 291.89% and a negative return on equity of 59.67%. The company’s quarterly revenue was up 94.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.75 earnings per share. Sell-side analysts anticipate that Y-mAbs Therapeutics, Inc. will post -1.7 earnings per share for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Royal Bank of Canada boosted its position in shares of Y-mAbs Therapeutics by 4.6% in the third quarter. Royal Bank of Canada now owns 15,560 shares of the company’s stock worth $444,000 after acquiring an additional 690 shares during the last quarter. DNB Asset Management AS boosted its position in shares of Y-mAbs Therapeutics by 6.4% in the fourth quarter. DNB Asset Management AS now owns 13,367 shares of the company’s stock worth $217,000 after acquiring an additional 801 shares during the last quarter. Point72 Hong Kong Ltd acquired a new stake in shares of Y-mAbs Therapeutics in the third quarter worth approximately $28,000. DekaBank Deutsche Girozentrale boosted its position in shares of Y-mAbs Therapeutics by 9.9% in the first quarter. DekaBank Deutsche Girozentrale now owns 14,400 shares of the company’s stock worth $172,000 after acquiring an additional 1,300 shares during the last quarter. Finally, Credit Suisse AG boosted its position in shares of Y-mAbs Therapeutics by 8.8% in the third quarter. Credit Suisse AG now owns 16,942 shares of the company’s stock worth $483,000 after acquiring an additional 1,375 shares during the last quarter. 60.50% of the stock is currently owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Company Profile (NASDAQ:YMAB)

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.

Recommended Stories

Want More Great Investing Ideas?

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.